Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
8th grade Avg
|
New words:
absence, add, agility, approach, Arginine, Asian, awarded, aware, Biomedical, biotech, borrowing, brentuximab, broad, burden, Chinese, cHL, choice, classical, concise, correct, countersued, declaratory, Deiminase, destructive, disciplined, Division, Dutch, duty, ehf, entrepreneurial, EPO, evident, examination, fiduciary, firm, force, Hodgkin, Honjo, immunoscience, inventorship, JCCP, Keytruda, Kingdom, Korman, leadership, lease, lesser, leverage, long, longest, lymphoma, maintain, maintained, MDL, monetary, monohydrate, Mylan, opposition, PAD, Padlock, par, permanently, petitioner, plateau, platinum, practicable, preemption, prepaid, presence, pretreated, prospective, PTC, pursue, reacquire, readily, reconsideration, Revlimid, revoked, rose, SCCHN, stem, stipulation, sued, Taiwan, top, treasury, unnamed, vedotin, ViiV, withheld
Removed:
abatacept, achievement, acquire, adequately, administered, advance, aggregate, aimed, amortized, approximate, assumed, ASV, asymptomatic, BCV, benchmark, beta, biopharma, Brazil, Bydureon, calcium, calculation, Calibr, Canada, carrying, CI, close, closing, collaborate, collect, combining, congestive, construct, continued, contract, create, daewoong, DCV, delivered, developing, discontinued, discount, discovering, disease, domestic, dual, earned, EGFR, ejection, eligible, entecavir, equal, equally, erosion, event, evolution, evolve, exercised, exit, exposure, factoring, FCPA, filling, floating, forecast, forecasted, formulation, fourth, fraction, gene, globally, Hanmi, hazard, heart, hedged, highly, imatinib, ImClone, immunology, immunotherapy, improve, inception, increasing, Indiana, ineffective, infected, infection, initiated, innate, inoperable, inquiry, instrument, invoiced, ipilimumab, Italy, IV, joint, key, KGaA, Korean, leading, located, manufacture, master, Mexico, minimally, modulating, molecule, monitored, Mount, Myalept, negative, nivolumab, objective, observed, occurring, offsetting, Ohio, Onglyza, open, originally, Otsuka, oversight, payable, peer, percentage, performed, personnel, platform, Portugal, privately, promotional, prostate, Prostvac, qualifying, RA, ratably, ratio, recorded, recourse, redemption, regulator, remeasured, remeasuring, reserve, responsibility, restore, restricted, restructuring, retain, retirement, returned, revised, ruled, satisfying, sensor, separately, shift, shown, simplified, small, sovereign, standalone, standpoint, substantially, sulfate, Symlin, symptomatic, synthesize, system, tablet, technology, temporarily, terminate, TGF, transformation, translation, Tribunal, ultimately, uncollectibility, underlying, uniQure, Valeant, variability, Vernon, vest, virology, weighted, workforce
Filing tables
Filing exhibits
Related press release
BMY similar filings
Filing view
External links
EXHIBIT 12.
Computation of Earnings to Fixed Charges
Ratio of Earnings to Fixed Charges: | Three Months Ended March 31, 2016 | Year Ended December 31, | |||||||||||||||||
2015 | 2014 | 2013 | 2012 | ||||||||||||||||
Dollars in Millions | |||||||||||||||||||
Earnings | |||||||||||||||||||
Earnings from continuing operations before income taxes | $ | 1,655 | $ | 2,077 | $ | 2,381 | $ | 2,891 | $ | 2,340 | |||||||||
Less: | |||||||||||||||||||
Noncontrolling interest in pre-tax income of subsidiaries | |||||||||||||||||||
that have not incurred fixed charges | 2 | 51 | 38 | 36 | 844 | ||||||||||||||
Equity in net income of affiliates | 26 | 83 | 107 | 166 | 183 | ||||||||||||||
Capitalized interest | 1 | 2 | 3 | — | — | ||||||||||||||
Adjusted Income | 1,626 | 1,941 | 2,233 | 2,689 | 1,313 | ||||||||||||||
Add: | |||||||||||||||||||
Fixed charges | 55 | 231 | 254 | 255 | 227 | ||||||||||||||
Distributed income of equity investments | 26 | 105 | 153 | 149 | 229 | ||||||||||||||
Total Earnings | $ | 1,707 | $ | 2,277 | $ | 2,640 | $ | 3,093 | $ | 1,769 | |||||||||
Fixed Charges | |||||||||||||||||||
Interest expense | $ | 43 | $ | 184 | $ | 203 | $ | 199 | $ | 182 | |||||||||
Capitalized interest | 1 | 2 | 3 | — | — | ||||||||||||||
One-third of rental expense(1) | 11 | 45 | 48 | 56 | 45 | ||||||||||||||
Total Fixed Charges | $ | 55 | $ | 231 | $ | 254 | $ | 255 | $ | 227 | |||||||||
Ratio of Earnings to Fixed Charges | 31.04 | 9.86 | 10.39 | 12.13 | 7.79 |
(1) Rents included in the computation consist of one-third of rental expense which the Company believes to be a reasonable estimate of an interest factor in its leases.
E-12-1